• Mashup Score: 0
    Once-weekly exenatide safe, effective for youths with type 2 diabetes - 3 year(s) ago

    Adolescents with type 2 diabetes were more likely to achieve HbA1c targets after 24 weeks of once-weekly exenatide compared with placebo, with trends observed toward decreased fasting plasma glucose and reduced body weight, data show. The incidence and prevalence of type 2 diabetes among children and adolescents are increasing, particularly among minority racial and ethnic groups, Raafat Bishai,

    Source: www.healio.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of EndocrineToday
      EndocrineToday

      ICYMI: “Exenatide was well tolerated, with a safety profile similar to other [GLP-1 receptor agonists]. It is a new treatment option for children and adolescents, conveniently administered once-weekly.” #diabetes #ADA2021 @ADA_DiabetesPro https://t.co/apkyOqZjfA

  • Mashup Score: 12
    Insulin Degludec Better Than Glargine for Nighttime Hypos in T1D - 3 year(s) ago

    In a head-to-head crossover study of 51 patients with type 1 diabetes and a history of nighttime hypoglycemia, insulin degludec halved the number of nighttime ‘lows’ compared with glargine U100.

    Source: Medscape
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Medscape
      Medscape

      Patients with T1D who use insulin degludec as their basal insulin had less than half the number of nocturnal hypoglycemia events compared to those who used insulin glargine U100. https://t.co/TWljd46EI7 #ADA2021 https://t.co/zD9A96hXjF

  • Mashup Score: 2
    Once-weekly exenatide safe, effective for youths with type 2 diabetes - 3 year(s) ago

    Adolescents with type 2 diabetes were more likely to achieve HbA1c targets after 24 weeks of once-weekly exenatide compared with placebo, with trends observed toward decreased fasting plasma glucose and reduced body weight, data show. The incidence and prevalence of type 2 diabetes among children and adolescents are increasing, particularly among minority racial and ethnic groups, Raafat Bishai,

    Source: www.healio.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of EndocrineToday
      EndocrineToday

      ICYMI: “The first once-weekly GLP-1 receptor agonist exenatide demonstrated superiority in reducing HbA1c at 24 weeks vs. placebo in children and adolescents with type 2 diabetes not optimally controlled." #ADA2021 @ADA_DiabetesPro https://t.co/apkyOqZjfA

  • Mashup Score: 0
    Once-weekly exenatide safe, effective for youths with type 2 diabetes - 3 year(s) ago

    Adolescents with type 2 diabetes were more likely to achieve HbA1c targets after 24 weeks of once-weekly exenatide compared with placebo, with trends observed toward decreased fasting plasma glucose and reduced body weight, data show. The incidence and prevalence of type 2 diabetes among children and adolescents are increasing, particularly among minority racial and ethnic groups, Raafat Bishai,

    Source: www.healio.com
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of GoHealio
      GoHealio

      Adolescents with type 2 #diabetes were more likely to reach HbA1c targets after 24 weeks of exenatide compared with placebo, according to an #ADA2021 presenter. @ADA_DiabetesPro https://t.co/bLWJTEHycY

    • Profile photo of EndocrineToday
      EndocrineToday

      Adolescents with type 2 #diabetes were more likely to reach HbA1c targets after 24 weeks of exenatide compared with placebo, according to an #ADA2021 presenter. @ADA_DiabetesPro https://t.co/apkyOqZjfA

  • Mashup Score: 0
    HealthDay Now: Diabetes Care in 2021 - 3 year(s) ago

    As the American Diabetes Association concluded its annual meeting, HealthDay spoke to Dr. Robert Gabbay, the ADA’s chief scientific and medical officer. Dr. …

    Source: YouTube
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HealthDayTweets
      HealthDayTweets

      WATCH NOW: Dr. Robert Gabbay of @AmDiabetesAssn shares highlights from #ADA2021 and addresses insulin prices and racial disparities in diabetes care. @Type2CEO https://t.co/YYgXM20z55

Load More